One vision —
a cancer-free future.
Unlike surgery, chemotherapy and radiation, cell and gene therapies harness the power of your immune system to destroy cancer cells without harming healthy tissue. We fund the research that will make this vision a reality.
ACGT attends Society for Immunotherapy for Cancer (SITC) Annual Meeting.
Cancer cell and gene therapy continues to be a rapidly expanding area of immuno-oncology with many sessions and presentations during the 2024 SITC conference.
FDA approves Aucatzyl CAR T-cell therapy to treat acute lymphoblastic leukemia (ALL)
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL)
Cancer survivor spotlight: Austin Schuetz
Austin Schuetz is a cancer survivor thanks to receiving CAR T-cell therapy for his leukemia.
ACGT Research Fellow spotlight: Hideho Okada
Hideho Okada was awarded a grant to develop a cell and gene therapy for a rare pediatric brain tumor.
ACGT awards grant for development of remote-controlled CAR T cells
This is the second research grant awarded to scientist Crystal Mackall, MD (Stanford University).
Our direct impact on eradicating all cancer.
Collaborating with partners and funding research fellows, we are transforming cancer treatments today while bringing the world closer to a cure for all cancers tomorrow.
37+
million dollars invested in groundbreaking research.
67
research fellows awarded grants.
41
top medical institutions and partners funded.
Join forces with the world’s leading researchers to finally identify cures.
Cell and gene therapies harness the power of a patient’s own immune system to destroy cancer cells without harming healthy tissue.
E. Antonio Chiocca, MD, PhD
Brigham and Women’s Hospital
Using viruses to infect glioblastoma cancer cells and engage a patient’s immune system to join the fight.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Juan Fueyo, MD
MD Anderson Cancer Center
ACGT is funding research that uses an oncolytic virus to fight glioblastoma, a deadly type of brain tumor.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
E. Antonio Chiocca, MD, PhD
Brigham and Women’s Hospital
Using viruses to infect glioblastoma cancer cells and engage a patient’s immune system to join the fight.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Juan Fueyo, MD
MD Anderson Cancer Center
ACGT is funding research that uses an oncolytic virus to fight glioblastoma, a deadly type of brain tumor.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
See what's new in cell and gene therapy.
Nov 11, 2024
Oct 11, 2023
100% of your donation will advance research to cure all cancers.
Your donation will help develop radical new cell and gene therapies that leverage the body’s own biology and immune system to control and ultimately eradicate cancer. 100% of donations directly support scientists working on breakthrough cancer cell and gene therapy research.
Donate Today